---

市場概況

---

レポートの範囲に応じて, 迅速な診断テスト (RDT), 迅速検査とも呼ばれます, 重症急性呼吸器症候群コロナウイルスの診断に使用される簡単で迅速な検査です 2 (SARS-CoV-2) 感染.

The COVID rapid diagnostic test market was valued at USD 18.7 billion in the base year and is projected to reach USD 7.5 十億, 年間複利成長率 (CAGR) の -10.90% 予測期間中.

The rising number of global COVID-19 cases and the presence of different variants have created a demand for early symptom detection. 1月に 2023, the World Health Organization (誰が) reported approximately 753 million confirmed cases of COVID-19 globally, up from over 645 million confirmed cases in December 2022. The highest number of new weekly cases in 2023 were reported in Japan (419,033), followed by China (158,687), 韓国 (148,261), ドイツ (64,545), そしてブラジル (51,176). さらに, 十一月に 2021, the WHO identified the omicron variant of the SARS-CoV-2 coronavirus and classified it as a variant of concern. The recent surge in COVID-19 cases has been linked to highly transmissible variants, including a subvariant known as BA.2 or “stealth omicron,” particularly in regions with lax safety protocols.

Rapid diagnostic tests offer quick results and are user-friendly. パンデミックの最中, companies focused on developing COVID-19 rapid diagnostic products, which further contributed to market growth. 例えば, 5月に 2022, BD launched a high-throughput molecular diagnostic combination test for SARS-CoV-2 and Influenza A/B on the BD SARS-CoV-2/Flu assay for the BD COR System. This automated multiplexed real-time RT-PCR test can detect and differentiate SARS-CoV-2, influenza A, and influenza B from a single nasal sample taken from patients displaying signs of respiratory viral infection.

Challenges such as product recalls due to quality control issues, stringent regulations and policies related to COVID-19 testing, and product approvals may hinder the growth of the COVID rapid diagnostic test market during the forecast period.

---

市場セグメンテーション

---

市場はさまざまな要因に基づいて分割されます, タイプも含めて, エンドユーザー, と地域.

タイプ別のセグメンテーション
Molecular Tests
Antigen Tests
Other Tests

エンドユーザーごとのセグメンテーション
Hospitals and Clinics
Laboratories and Diagnostics Centers
その他のエンドユーザー

地域ごとのセグメンテーション
北米 – アメリカ, カナダ, そしてメキシコ
ヨーロッパ – イギリス, ドイツ, フランス, イタリア, スペイン, およびその他のヨーロッパ
アジア太平洋地域 – 中国, 日本, インド, 韓国, オーストラリア, およびその他のアジア太平洋地域
ラテンアメリカ – ブラジル, アルゼンチン, およびその他のラテンアメリカ諸国
中東とアフリカ – 南アフリカ, GCC, およびその他の中東およびアフリカ

The hospitals and clinics segment was the largest end user in the market studied. In terms of end users, the hospitals and clinics segment held the major share in the studied market with a value of USD 11,224.91 百万で 2022. It is expected to witness a compound annual growth rate (CAGR) の -11.13% 予測期間にわたって. Hospitals play a crucial role in healthcare systems as they are well-equipped with advanced kits, reagents, and instruments for diagnosing and monitoring infectious diseases. They are also the primary users of test kits for diagnosis. The growth of this segment is driven by an increase in the utilization of outpatient services and the affordability of care and diagnosis. クリニック, 一方で, are smaller healthcare settings that offer primary healthcare services such as general checkups, sample collection, and routine tests.

In terms of test types, the antigen test segment had the largest share in the market studied. The antigen test segment held the major share in the studied market with a value of USD 12,575.06 百万で 2022. It is expected to witness a CAGR of -10.76% 予測期間にわたって. Antigen tests identify possible antigens, which are small proteins that make up the virus, in a patient’s sample. These tests provide a faster and less expensive way to diagnose active SARS-CoV-2 infection compared to nucleic acid amplification tests or molecular tests.

The molecular tests segment, which includes RT-PCR or nucleic acid amplification tests (NAATs), is expected to register a significant CAGR over the forecast period. Molecular tests amplify bits of viral RNA to detect viral infection through specialized testing. This segment primarily includes polymerase chain reaction (PCR) tests, loop-mediated isothermal amplification (LAMP), and clustered, regularly interspaced short palindromic repeat (CRISPR)-based assays. Molecular testing offers a higher level of selectivity and precision for COVID-19 diagnosis, making it the recommended gold standard by authorities such as the World Health Organization (誰が), European Union (EU), and the U.S. 食品医薬品局 (FDA). The market for molecular tests is positively impacted by the launch and approval of several innovative molecular diagnostic products. 例えば, miDiagnostics launched an ultrafast COVID-19 PCR test based on silicon chip technology, providing results in about 30 minutes. Sense Biodetection received CE Marking for Veros COVID-19, a fully integrated molecular diagnostic test that provides laboratory-quality results in 15 minutes.

---

競争環境

---

The market for COVID rapid diagnostic tests exhibits a moderate level of fragmentation, with several prominent players operating within it. Noteworthy companies in this market include Abbott Laboratories, F. Hoffmann-La Roche Ltd, Siemens Healthcare GmbH, bioMérieux SA, Quest Diagnostics Incorporated, and Danaher Corporation, とりわけ.

Key Companies Profiled in this report include Abbott Laboratories, Thermo Fisher Scientific Inc., Cue Health Inc., Acon Laboratories, 株式会社, ダナハーコーポレーション (Beckman Coulter, 株式会社), F. Hoffmann-La Roche Ltd, Siemens Healthcare AG, Quidel Corporation, bioMerieux SA, Quest Diagnostics Incorporated, PerkinElmer Inc., Creative Diagnostics, CTK Biotech, QIAGEN.

---

最近の業界の発展

---

1月に 2023, the Government of Canada granted approval for the Artron Laboratories COVID-19 Antigen Home Test, a rapid self-testing kit designed for detecting COVID antigens.

1月に 2023, the Government of Canada also approved the Biomedomics Cov-scan Rapid Antigen Test for point-of-care testing purposes.

---

主な質問への回答

---

この市場の調査期間はどれくらいですか?
What is the rate of growth for the COVID Rapid Diagnostic Test Market?
Which region exhibits the highest growth rate in the COVID Rapid Diagnostic Test Market?
Which region holds the largest share in the COVID Rapid Diagnostic Test Market?
Who are the major players in the COVID Rapid Diagnostic Test Market?